文献速递湿疹皮炎与荨麻疹

每日使用润肤剂「plus」对特应性皮炎患者外用糖皮质激素用量的影响:一项开放随机对照研究

Impact of daily use of emollient 'plus' on corticosteroid consumption in patients with atopic dermatitis: An open, randomized controlled study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-04-24

一项开放、单中心、随机对照研究纳入119例轻中度特应性皮炎患者(SCORAD 20-30),随机分为每日两次使用润肤剂「plus」组或继续常规润肤剂对照组,共28天,两组均可按需使用外用糖皮质激素。结果显示润肤剂「plus」组较对照组外用糖皮质激素用量更少、使用天数更少、每日涂抹次数更少,而疗效与耐受性无显著差异。

要点

  • 润肤剂「plus」组第28天时外用糖皮质激素平均用量6.03 g,低于对照组9.16 g(p=0.041)。
  • 润肤剂「plus」组使用糖皮质激素的天数占比37.5%,低于对照组46.9%(p=0.0256)。
  • 两组在SCORAD、PO-SCORAD、局部SCORAD、生活质量及耐受性评估上无显著差异。

核心结论

  • 在基线至第28天期间,润肤剂「plus」组较对照组在外用糖皮质激素用量、每日涂抹次数和使用天数上均显著减少,而疗效维持且两组所有临床评估及耐受性无显著差异。

研究设计与样本

  • 开放、单中心、随机对照研究,纳入轻中度特应性皮炎(SCORAD 20-30)患者,按1:1随机分为每日两次使用润肤剂「plus」组(28天)或继续常规润肤剂对照组,两组均按皮肤科医生处方按需使用外用糖皮质激素。
  • 符合方案集(PP)共纳入119例患者,平均年龄26.50±17.5岁(最小-最大3-71岁)。

主要发现

  • 基线至第28天,润肤剂「plus」组外用糖皮质激素平均用量为6.03 g,对照组为9.16 g(p=0.041)。
  • 润肤剂「plus」组使用糖皮质激素的天数占比为37.5%,对照组为46.9%(p=0.0256)。
  • 润肤剂「plus」组每日涂抹次数为0.55次,对照组为0.71次(p=0.0203)。
  • 两组在SCORAD、PO-SCORAD、局部SCORAD、皮肤感觉评分、AD负担量表、患者受益指数>1以及受试者和研究者疗效与耐受性问卷评估方面均观察到相似改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emollients are the baseline treatment for mild or moderate atopic dermatitis (AD) to improve the epidermal barrier and provide anti-irritant and anti-pruritic effects. Emollient 'plus' can influence the skin microbiome of atopic eczema patients. OBJECTIVES: To evaluate the benefits of using Emollient 'plus' to reduce corticosteroid consumption. METHODS: In an open, single-centre, randomized, controlled study, patients with mild to moderate AD (Severity scoring of AD [SCORAD] score 20-30) were randomized 1:1 to apply the Emollient 'plus' twice daily for 28 days or to continue with their usual classical emollient (Control group). In addition, each patient received topical corticosteroids to use when necessary and according to the dermatologist's prescription. Assessments included SCORAD, PO-SCORAD, local SCORAD, quality of life questionnaires, and tolerability. RESULTS: A total of 119 patients were included in the PP population with a mean age of 26.50 ± 17.5 years old (min-max 3-71 years). Between baseline and day 28, the mean amount of corticosteroid used was lower for the Emollient 'plus' versus Control group (6.03 vs. 9.16 g; p = 0.041) and corticosteroid was applied on fewer days (37.5% vs. 46.9% of days; p = 0.0256) with fewer applications per day (0.55 vs. 0.71 applications per day; p = 0.0203). Similar improvements were observed in both groups for SCORAD, PO-SCORAD, local SCORAD, skin sensation score, AD burden scale, patient benefit index >1, as well as subject and investigator efficacy and tolerability questionnaire assessments. CONCLUSIONS: Between baseline and day 28, there was significant corticosteroid-sparing in the Emollient 'plus' group compared to the Control group in quantity, number of applications per day and number of days of use, whilst efficacy was maintained with no significant differences between the two groups for all clinical evaluations, as well as for tolerability.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Zelenkova H, Kerob D, Salah S, et al. Impact of daily use of emollient 'plus' on corticosteroid consumption in patients with atopic dermatitis: An open, randomized controlled study. J Eur Acad Dermatol Venereol. 2023. PMID: 37092256. doi:10.1111/jdv.18947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。